These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15582265)

  • 1. Induction of P815 tumor immunity by DNA-based recombinant Semliki Forest virus or replicon DNA expressing the P1A gene.
    Ni B; Lin Z; Zhou L; Wang L; Jia Z; Zhou W; Diciommo DP; Zhao J; Bremner R; Wu Y
    Cancer Detect Prev; 2004; 28(6):418-25. PubMed ID: 15582265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preventive and therapeutic effect of genetic vaccine based on recombinant alpha virus against mouse mastocytoma P815].
    Ni B; Yang RG; Li YQ; Wu YZ
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Jan; 20(1):45-8. PubMed ID: 15182620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene.
    Colmenero P; Liljeström P; Jondal M
    Gene Ther; 1999 Oct; 6(10):1728-33. PubMed ID: 10516722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.
    Näslund TI; Uyttenhove C; Nordström EK; Colau D; Warnier G; Jondal M; Van den Eynde BJ; Liljeström P
    J Immunol; 2007 Jun; 178(11):6761-9. PubMed ID: 17513723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular electroporation of a P1A-encoding plasmid vaccine delays P815 mastocytoma growth.
    Vandermeulen G; Uyttenhove C; De Plaen E; Van den Eynde BJ; Préat V
    Bioelectrochemistry; 2014 Dec; 100():112-8. PubMed ID: 24342164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semliki forest virus and Kunjin virus RNA replicons elicit comparable cellular immunity but distinct humoral immunity.
    Tannis LL; Gauthier A; Evelegh C; Parsons R; Nyholt D; Khromykh A; Bramson JL
    Vaccine; 2005 Jul; 23(33):4189-94. PubMed ID: 16005737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
    Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
    Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing immune responses using suicidal DNA vaccines.
    Berglund P; Smerdou C; Fleeton MN; Tubulekas I; Liljeström P
    Nat Biotechnol; 1998 Jun; 16(6):562-5. PubMed ID: 9624688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles.
    Goldberg SM; Bartido SM; Gardner JP; Guevara-Patiño JA; Montgomery SC; Perales MA; Maughan MF; Dempsey J; Donovan GP; Olson WC; Houghton AN; Wolchok JD
    Clin Cancer Res; 2005 Nov; 11(22):8114-21. PubMed ID: 16299244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition.
    de Mare A; Lambeck AJ; Regts J; van Dam GM; Nijman HW; Snippe H; Wilschut J; Daemen T
    Gene Ther; 2008 Mar; 15(6):393-403. PubMed ID: 18004406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response.
    Colmenero P; Berglund P; Kambayashi T; Biberfeld P; Liljeström P; Jondal M
    Gene Ther; 2001 Sep; 8(17):1307-14. PubMed ID: 11571567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice.
    Lyons JA; Sheahan BJ; Galbraith SE; Mehra R; Atkins GJ; Fleeton MN
    Gene Ther; 2007 Mar; 14(6):503-13. PubMed ID: 17167497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immune response induced by HIV DNA vaccine combined with recombinant adeno-associated virus].
    Liu YZ; Zhou L; Wang Q; Ye SQ; Li HX; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep; 18(3):251-4. PubMed ID: 15640860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A vaccination strategy consisting of Semliki-Forest-virus (SFV) DNA prime and fowlpox-virus boost significantly protects mice from a recombinant (HIV-1) vaccinia-virus infection.
    Quintana-Vázquez D; Vázquez-Blomquist DM; Galbán Rodríguez E; Herrera Buch AM; Duarte Cano CA
    Biotechnol Appl Biochem; 2005 Feb; 41(Pt 1):59-66. PubMed ID: 15099194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles.
    Murphy AM; Morris-Downes MM; Sheahan BJ; Atkins GJ
    Gene Ther; 2000 Sep; 7(17):1477-82. PubMed ID: 11001367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression.
    Colmenero P; Chen M; Castaños-Velez E; Liljeström P; Jondal M
    Int J Cancer; 2002 Apr; 98(4):554-60. PubMed ID: 11920615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity.
    Cheng WF; Lee CN; Su YN; Chai CY; Chang MC; Polo JM; Hung CF; Wu TC; Hsieh CY; Chen CA
    Cancer Gene Ther; 2006 Sep; 13(9):873-85. PubMed ID: 16645621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
    Chen PW; Ksander BR
    Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
    Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.